Tilray (NASDAQ:TLRY) Issues Quarterly Earnings Results

Tilray (NASDAQ:TLRY) announced its quarterly earnings data on Friday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.07), Zacks reports. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The business had revenue of $210.90 million during the quarter, compared to analysts’ expectations of $216.34 million. Tilray’s quarterly revenue was up 8.7% on a year-over-year basis. Tilray updated its FY 2025 guidance to EPS.

Tilray Trading Down 12.0 %

Shares of NASDAQ TLRY traded down $0.17 during mid-day trading on Friday, hitting $1.21. The company’s stock had a trading volume of 30,857,303 shares, compared to its average volume of 45,809,570. The company’s fifty day simple moving average is $1.37 and its 200-day simple moving average is $1.62. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -4.46 and a beta of 2.08. Tilray has a one year low of $1.14 and a one year high of $2.97. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57.

Insider Buying and Selling

In other news, CFO Carl A. Merton purchased 26,000 shares of Tilray stock in a transaction dated Friday, November 15th. The shares were bought at an average cost of $1.36 per share, with a total value of $35,360.00. Following the completion of the transaction, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.87% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, Roth Mkm decreased their price target on Tilray from $2.00 to $1.75 and set a “neutral” rating for the company in a research note on Friday, October 11th.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.